PMID- 36741577
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230207
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 13
DP  - 2022
TI  - Are serum levels of inflammatory markers associated with the severity of symptoms 
      of bipolar disorder?
PG  - 1063479
LID - 10.3389/fpsyt.2022.1063479 [doi]
LID - 1063479
AB  - BACKGROUND: To explore the relationship between serum levels of inflammatory 
      markers and symptomatic severity of bipolar disorder (BD). MATERIALS AND METHODS: 
      A cross-sectional study was conducted on 126 BD patients with current depressive 
      episode (BDD), 102 BD patients with current mixed or (hypo)manic episode (BDM) 
      and 94 healthy controls (HC). All participants were drug-naive and had no current 
      active physical illness associated with inflammatory response or history of 
      substance abuse. Fasting serum levels of CRP, leptin (LEP), adiponectin (ADP), 
      visfatin (VIS), TNF-alpha, IL-2, IL-6, IL-10, IL-17), and monocyte chemoattractant 
      protein-1 (MCP-1) were measured with enzyme-linked immunosorbent assay (ELISA). 
      Symptomatic severity of BD was assessed with HAMD-17 and YMRS. Generalized linear 
      model was used to determine the association between the serum levels of 
      inflammatory markers and symptomatic severity of BD. RESULTS: The serum levels of 
      IL-6, IL-10 and IL-17, and the IL-6/IL-10 ratio were significantly lower in mild 
      BDD than in HC. In moderate BDD, the serum levels of MCP, IL-6 and IL-17 were 
      significantly lower than in HC. In severe BDD, the serum level of ADP, MCP-1, 
      IL-10 and IL-17and the IL-17/IL-10 ratio were significantly lower than in HC. The 
      serum levels of TNF-alpha and the IL-6/IL-10 ratio were significantly higher in mild 
      BDM than in HC. In moderate BDM, the serum level of VIS, IL-2, and IL-17 were 
      significantly higher than in HC, but the IL-6/IL-10 ratio was significantly lower 
      than in control. In severe BDM, the serum levels of IL-6 and IL-17 and the ratios 
      of IL-6/IL-10 and IL-17/IL-10 were significantly lower than in HC, but the 
      neutrophil/lymphocyte ratio was significantly higher than in HC. CONCLUSION: In 
      BDD, immune-inhibition is persistently predominant, while in mild-to-moderate 
      BDM, immune system is activated but inhibited in severe BDM. The dynamic change 
      of serum inflammatory markers suggests that alteration of peripheral inflammatory 
      markers in BD is state-dependent instead of trait-marked.
CI  - Copyright (c) 2023 Wu, Chen, Liao, Yang, Liang, Guan and Gan.
FAU - Wu, Xiuhua
AU  - Wu X
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Chen, Zhongcheng
AU  - Chen Z
AD  - Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Liao, Yingtao
AU  - Liao Y
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Yang, Zhihua
AU  - Yang Z
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Liang, Xiaolin
AU  - Liang X
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Guan, Nianhong
AU  - Guan N
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Gan, Zhaoyu
AU  - Gan Z
AD  - Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20230120
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC9894870
OTO - NOTNLM
OT  - bipolar disorder
OT  - inflammatory markers
OT  - pathophysiology
OT  - stage
OT  - symptomatic severity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/07 06:00
MHDA- 2023/02/07 06:01
PMCR- 2023/01/20
CRDT- 2023/02/06 03:33
PHST- 2022/10/07 00:00 [received]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/02/06 03:33 [entrez]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/07 06:01 [medline]
PHST- 2023/01/20 00:00 [pmc-release]
AID - 10.3389/fpsyt.2022.1063479 [doi]
PST - epublish
SO  - Front Psychiatry. 2023 Jan 20;13:1063479. doi: 10.3389/fpsyt.2022.1063479. 
      eCollection 2022.